<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005941</url>
  </required_header>
  <id_info>
    <org_study_id>1477.00</org_study_id>
    <secondary_id>FHCRC-1477.00</secondary_id>
    <secondary_id>NCI-G00-1784</secondary_id>
    <secondary_id>CDR0000067816</secondary_id>
    <nct_id>NCT00005941</nct_id>
  </id_info>
  <brief_title>Peripheral Stem Cell Transplant, White Blood Cell Infusions, Chemotherapy, and Radiation Therapy in Treating Patients With Recurrent Metastatic Cervical or Vaginal Cancer</brief_title>
  <official_title>Phase II Pilot Trial of Non-Myeloablative Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation Using Fludarabine, Low Dose TBI and Post-Transplant Cyclosporine and Mycophenolate Mofetil Followed by Donor Lymphocyte Infusion for Therapy of Advanced or Metastatic Human Papilloma Virus (HPV) - Associated Cervical Carcinoma Refractory to Standard Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and radiation therapy&#xD;
      before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.&#xD;
      It also stops the patient's immune system from rejecting the donor's stem cells. The donated&#xD;
      stem cells may replace the patient's immune system and help destroy any remaining cancer&#xD;
      cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor&#xD;
      lymphocyte infusion) after the transplant may help increase this effect. Sometimes the&#xD;
      transplanted cells from a donor can also make an immune response against the body's normal&#xD;
      cells. Giving cyclosporine and mycophenolate mofetil after the transplant may stop this from&#xD;
      happening.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well donor peripheral stem cell transplant plus&#xD;
      chemotherapy and total-body irradiation followed by donor white blood cell infusion work in&#xD;
      treating patients with recurrent metastatic or locally advanced cancer of the cervix or&#xD;
      vagina that is associated with human papillomavirus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the partial or complete response in patients with recurrent metastatic or&#xD;
           locally advanced human papillomavirus (HPV)-associated cervical or vaginal carcinoma&#xD;
           treated with a nonmyeloablative regimen comprising fludarabine and low-dose total body&#xD;
           irradiation followed by allogeneic peripheral blood stem cell transplantation,&#xD;
           cyclosporine, mycophenolate mofetil, and donor lymphocyte infusion.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Determine whether this regimen induces engraftment and donor chimerism in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the HPV-E6 and HPV-E7 specific T-cell responses in selected patients treated&#xD;
           with this regimen.&#xD;
&#xD;
      OUTLINE: This is a pilot study.&#xD;
&#xD;
      Patients receive conditioning therapy comprising fludarabine IV on days -4 to -2 and low-dose&#xD;
      total body irradiation on day 0. Filgrastim (G-CSF)-mobilized allogeneic peripheral blood&#xD;
      stem cells are infused on day 0.&#xD;
&#xD;
      Patients also receive oral cyclosporine twice daily on days -3 to 35 and then tapered until&#xD;
      day 56. Mycophenolate mofetil is administered orally twice daily on days 0-27.&#xD;
&#xD;
      Patients with disease progression and no graft-versus-host disease on day 56 receive&#xD;
      nonmobilized donor lymphocyte infusion (DLI) over 30 minutes on day 65. DLI may be repeated&#xD;
      every 65 days for up to 4 doses.&#xD;
&#xD;
      Patients are followed weekly for 3 months, monthly for 6 months, every 6 months for 2 years,&#xD;
      and then annually for 5 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1999</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Partial or complete response</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engraftment and donor chimerism</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPV-E6 and E7-specific T cell responses</measure>
  </secondary_outcome>
  <condition>Cervical Cancer</condition>
  <condition>Vaginal Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic allogeneic lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed recurrent metastatic or locally advanced cervical or vaginal&#xD;
             carcinoma that is not curable with surgery or radiotherapy&#xD;
&#xD;
               -  Tumor is human papillomavirus positive by polymerase chain reaction&#xD;
&#xD;
          -  Bidimensionally measurable disease by clinical examination or radiographic imaging&#xD;
&#xD;
          -  Availability of an genotypically HLA-identical sibling donor (excluding identical&#xD;
             twins)&#xD;
&#xD;
          -  No brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Under 65&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 80-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT and SGPT no greater than 2 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine clearance at least 40 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Cardiac ejection fraction at least 40%&#xD;
&#xD;
          -  No history of congestive heart failure&#xD;
&#xD;
          -  No poorly controlled hypertension&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No severe defects in pulmonary function&#xD;
&#xD;
          -  No supplementary continuous oxygen&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 12 months after study&#xD;
             completion&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Concurrent growth factors for severe persistent or febrile neutropenia after&#xD;
             transplantation allowed&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Nash, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutchinson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>March 31, 2010</last_update_submitted>
  <last_update_submitted_qc>March 31, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2010</last_update_posted>
  <keyword>stage III cervical cancer</keyword>
  <keyword>recurrent cervical cancer</keyword>
  <keyword>stage IVB cervical cancer</keyword>
  <keyword>stage IVA cervical cancer</keyword>
  <keyword>stage III vaginal cancer</keyword>
  <keyword>stage IVA vaginal cancer</keyword>
  <keyword>stage IVB vaginal cancer</keyword>
  <keyword>recurrent vaginal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Vaginal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

